SCHEMBL4355452

SCHEMBL4355452

Cc1c(Cl)cc(N(S)C(=O)NCCc2ccccc2)c(O)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
HSD17B2 P37059 1/20 0.43
NPC1 O15118 6/20 0.42
RAB9A P51151 6/20 0.42
TAAR1 Q96RJ0 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 1/20 0.40
PLAAT3 P53816 4/20 0.40
PLAAT5 Q96KN8 4/20 0.40
PLAAT2 Q9NWW9 4/20 0.40
PLAAT4 Q9UL19 4/20 0.40
PTGS2 P35354 1/20 0.40
CA12 O43570 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351442 0.82 CA1 (0.45) CA1CA2HSD17B2NPC1RAB9A
SCHEMBL4358550 0.80 EPHX2 (0.39) CA1CA2TRPV1L3MBTL1PTGS2
SCHEMBL4356059 0.80 NPC1 (0.50) CA1CA2HSD17B2NPC1RAB9A
SCHEMBL4349377 0.80 EGFR (0.41) NPC1RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL4350885 0.80 NPC1 (0.42) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL4346980 0.78 CA2 (0.48) CA1CA2HSD17B2NPC1RAB9A
SCHEMBL4344569 0.77 LMNA (0.41) CA1CA2HSD17B2NPC1RAB9A
SCHEMBL4350095 0.77 MAPT (0.46) CA2NPC1RAB9ATRPV1SMN1; SMN2
SCHEMBL4345395 0.76 CA1 (0.49) CA1CA2HSD17B2NPC1RAB9A
SCHEMBL4341271 0.75 NPC1 (0.52) CA1CA2HSD17B2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 CA1 374/4885CA2 2053/4885HSD17B2 246/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 CA1 532/4885CA2 1651/4885HSD17B2 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.